Novo Nordisk Launches Wegovy Weight-Loss Pill in US, Intensifying Price Competition

Novo Nordisk has launched its Wegovy weight-loss pill in the US at a significantly lower price than injectable alternatives. The once-daily pill is the first and only GLP-1 tablet on the market and recently received regulatory approval. Self-paying patients can access the starting dose for $149 a month, far below typical injection prices. The pill offers a needle-free option that may appeal to more patients. The move accelerates a price war with rivals including Eli Lilly, which sells competing injections. Novo hopes the launch will help regain market share after recent profit warnings. The Wegovy pill is currently approved only in the US, with a UK decision expected later this year.